Michael Richman is president and CEO of NextCure, a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. From 2007 to 2015, and prior to its acquisition by AstraZeneca in 2013, he was president and CEO of Amplimmune when it was a privately held biologics company focused on cancer and autoimmune diseases. From 2002 through 2007, he was the executive vice president and chief operating officer of MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, autoimmune disorders and infectious diseases.

Richman has more than 30 years of experience working in research, intellectual property and business development capacities in companies, such as Chiron Corporation (now Novartis) and MedImmune (prior to AstraZeneca’s acquisition), where he was senior vice president corporate development. While at MedImmune, Richman was responsible for all business development, licensing, intellectual property, legal affairs, project management and strategic planning functions, and drove many significant transactions during that period.

Richman is a member of the board of directors of several public and private companies. Richman obtained his bachelor’s in genetics/molecular biology at the University of California at Davis and his MSBA in international business at San Francisco State University.